PE20211067A1 - Benzimidazoles sustituidos como inhibidores de pad4 - Google Patents
Benzimidazoles sustituidos como inhibidores de pad4Info
- Publication number
- PE20211067A1 PE20211067A1 PE2021000170A PE2021000170A PE20211067A1 PE 20211067 A1 PE20211067 A1 PE 20211067A1 PE 2021000170 A PE2021000170 A PE 2021000170A PE 2021000170 A PE2021000170 A PE 2021000170A PE 20211067 A1 PE20211067 A1 PE 20211067A1
- Authority
- PE
- Peru
- Prior art keywords
- crdrd
- substituted
- pad4
- useful
- membered heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862715858P | 2018-08-08 | 2018-08-08 | |
| PCT/US2019/045424 WO2020033488A1 (en) | 2018-08-08 | 2019-08-07 | Substituted benzimidazoles as pad4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211067A1 true PE20211067A1 (es) | 2021-06-09 |
Family
ID=67766299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000170A PE20211067A1 (es) | 2018-08-08 | 2019-08-07 | Benzimidazoles sustituidos como inhibidores de pad4 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220402950A1 (enExample) |
| EP (1) | EP3833438B1 (enExample) |
| JP (1) | JP7483678B2 (enExample) |
| KR (1) | KR102825194B1 (enExample) |
| CN (1) | CN112805066A (enExample) |
| AU (1) | AU2019318415A1 (enExample) |
| BR (1) | BR112021002089A2 (enExample) |
| CA (1) | CA3108871A1 (enExample) |
| CL (1) | CL2021000292A1 (enExample) |
| CO (1) | CO2021001219A2 (enExample) |
| EA (1) | EA202190464A1 (enExample) |
| ES (1) | ES2973714T3 (enExample) |
| IL (1) | IL280641A (enExample) |
| MX (1) | MX2021001471A (enExample) |
| PE (1) | PE20211067A1 (enExample) |
| SG (1) | SG11202101176YA (enExample) |
| TW (1) | TW202019411A (enExample) |
| WO (1) | WO2020033488A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3833440A1 (en) | 2018-08-08 | 2021-06-16 | Bristol-Myers Squibb Company | Indole and azaindole inhibitors of pad enzymes |
| ES2929200T3 (es) * | 2018-08-08 | 2022-11-25 | Bristol Myers Squibb Co | Tienopirroles sustituidos como inhibidores de PAD4 |
| ES2956090T3 (es) | 2018-08-08 | 2023-12-13 | Bristol Myers Squibb Co | Inhibidores de bencimidazol de enzimas PAD |
| CN115298175B (zh) | 2020-02-06 | 2024-05-07 | 百时美施贵宝公司 | 可用作免疫抑制剂的大环pad4抑制剂 |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
| MX2022013615A (es) | 2020-04-30 | 2022-11-16 | Gilead Sciences Inc | Inhibidores de macrociclo de peptidilarginina deiminasas. |
| EP4267562A1 (en) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| TW202233174A (zh) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
| CN116492462B (zh) * | 2023-02-03 | 2023-09-22 | 山东第一医科大学附属眼科医院(山东省眼科医院) | Pad4抑制剂在防治角膜移植术后免疫排斥反应中的应用 |
| WO2025024265A1 (en) | 2023-07-21 | 2025-01-30 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad4 modulators |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2611010C2 (ru) * | 2012-07-26 | 2017-02-17 | Глаксо Груп Лимитед | 2-(Азаиндол-2-ил)бензимидазолы в качестве ингибиторов PAD4 |
| WO2016185279A1 (en) | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
| AR107030A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| US10703741B2 (en) | 2016-07-27 | 2020-07-07 | Padlock Therapeutics, Inc. | Covalent inhibitors of PAD4 |
-
2019
- 2019-08-07 MX MX2021001471A patent/MX2021001471A/es unknown
- 2019-08-07 JP JP2021506621A patent/JP7483678B2/ja active Active
- 2019-08-07 US US17/265,844 patent/US20220402950A1/en active Pending
- 2019-08-07 ES ES19759133T patent/ES2973714T3/es active Active
- 2019-08-07 AU AU2019318415A patent/AU2019318415A1/en not_active Abandoned
- 2019-08-07 SG SG11202101176YA patent/SG11202101176YA/en unknown
- 2019-08-07 CN CN201980064958.8A patent/CN112805066A/zh active Pending
- 2019-08-07 PE PE2021000170A patent/PE20211067A1/es unknown
- 2019-08-07 BR BR112021002089-6A patent/BR112021002089A2/pt not_active Application Discontinuation
- 2019-08-07 TW TW108128157A patent/TW202019411A/zh unknown
- 2019-08-07 KR KR1020217006450A patent/KR102825194B1/ko active Active
- 2019-08-07 EA EA202190464A patent/EA202190464A1/ru unknown
- 2019-08-07 CA CA3108871A patent/CA3108871A1/en active Pending
- 2019-08-07 WO PCT/US2019/045424 patent/WO2020033488A1/en not_active Ceased
- 2019-08-07 EP EP19759133.2A patent/EP3833438B1/en active Active
-
2021
- 2021-02-03 CL CL2021000292A patent/CL2021000292A1/es unknown
- 2021-02-03 CO CONC2021/0001219A patent/CO2021001219A2/es unknown
- 2021-02-04 IL IL280641A patent/IL280641A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021000292A1 (es) | 2021-06-11 |
| IL280641A (en) | 2021-03-25 |
| CN112805066A (zh) | 2021-05-14 |
| BR112021002089A2 (pt) | 2021-05-04 |
| MX2021001471A (es) | 2021-04-28 |
| CO2021001219A2 (es) | 2021-02-17 |
| AU2019318415A1 (en) | 2021-03-25 |
| SG11202101176YA (en) | 2021-03-30 |
| WO2020033488A1 (en) | 2020-02-13 |
| US20220402950A1 (en) | 2022-12-22 |
| EP3833438B1 (en) | 2024-02-07 |
| JP7483678B2 (ja) | 2024-05-15 |
| JP2021534097A (ja) | 2021-12-09 |
| KR20210042932A (ko) | 2021-04-20 |
| ES2973714T3 (es) | 2024-06-24 |
| KR102825194B1 (ko) | 2025-06-24 |
| EP3833438A1 (en) | 2021-06-16 |
| TW202019411A (zh) | 2020-06-01 |
| EA202190464A1 (ru) | 2021-06-16 |
| CA3108871A1 (en) | 2020-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211068A1 (es) | Inhibidores tipo indol y azaindol de enzimas pad | |
| NI201800093A (es) | Inhibidores de mcl1 macrocíclicos para tratar el cáncer | |
| PE20140966A1 (es) | Quinazolincarboxamida azetidinas | |
| PE20060527A1 (es) | COMPUESTOS DE CARBONILO COMO INHIBIDORES DEL FACTOR Xa | |
| EA201991127A1 (ru) | ЦИКЛОБУТАН- И АЗЕТИДИНСОДЕРЖАЩИЕ МОНО- И СПИРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНА αV | |
| CR20200263A (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
| PE20090698A1 (es) | Derivados de alcoholes de 1-fenil-2-piridinilalquilo como inhibidores de la fosfodiesterasa | |
| PE20160654A1 (es) | Compuestos de inhibidor de autotaxina | |
| AR059590A1 (es) | Inhibidores de quinasa basados en la hidantoina | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| PH12014500947B1 (en) | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | |
| PE20040937A1 (es) | Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4) | |
| EA201990904A1 (ru) | 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы | |
| NZ768368A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| PH12021550742A1 (en) | Indolinone compounds for use as map4k1 inhibitors | |
| UY31986A (es) | Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| PE20141064A1 (es) | Compuestos de ester boronato y composciones farmaceuticas de los mismos | |
| BR112014004310B8 (pt) | Composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto | |
| PE20152032A1 (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-il | |
| EA201000884A1 (ru) | Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| BR112022017382A2 (pt) | Composto, composição farmacêutica, uso do composto, e, métodos para tratar ou prevenir uma doença relacionada a ep4 e para tratar uma doença selecionada a partir de uma doença inflamatória, uma dor, um câncer, uma doença metabólica e uma doença do sistema urinário | |
| EA201391537A1 (ru) | ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 | |
| PE20160284A1 (es) | Derivados de amida como antogonistas del receptor de acido lisofosfatidico | |
| PE20121688A1 (es) | Compuestos de biciclo[3.1.0]hexano como agonistas de mglu2 |